GT Biopharma (GTBP) Short Interest Ratio & Short Volume → [FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (From Crypto 101 Media) (Ad) Free GTBP Stock Alerts $3.26 +0.21 (+6.89%) (As of 05/16/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media GT Biopharma Short Interest DataCurrent Short Volume6,000 sharesPrevious Short Volume3,300 sharesChange Vs. Previous Month+81.82%Dollar Volume Sold Short$18,000.00Short Interest Ratio / Days to Cover0.5Last Record DateApril 30, 2024Outstanding Shares1,380,000 sharesFloat Size1,240,000 sharesShort Percent of Float0.48%Today's Trading Volume12,061 sharesAverage Trading Volume11,070 sharesToday's Volume Vs. Average109% Short Selling GT Biopharma ? Sign up to receive the latest short interest report for GT Biopharma and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatGTBP Short Interest Over TimeGTBP Days to Cover Over TimeGTBP Percentage of Float Shorted Over Time Ad Porter & CompanyElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. GT Biopharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/20246,000 shares $18,000.00 +81.8%0.5%0.5 $3.00 4/15/20243,300 shares $12,408.00 -62.5%0.3%0.3 $3.76 3/31/20248,800 shares $38,984.00 +79.6%0.7%0.7 $4.43 3/15/20244,900 shares $22,687.00 -14.0%0.4%0.4 $4.63 2/29/20245,700 shares $24,282.00 +72.7%0.5%0.6 $4.26 2/15/20243,300 shares $13,200.00 +312.5%0.3%0.4 $4.00 Get the Latest News and Ratings for GTBP and Related StocksEnter your email address below to receive the latest news and analysts' ratings for GT Biopharma and its competitors with MarketBeat's FREE daily newsletter. 1/31/2024800 shares $4,752.00 -98.6%0.1%0.1 $5.94 1/15/202458,800 shares $13,171.20 +150.2%0.2%0.4 $0.22 12/31/202323,500 shares $5,992.50 -64.8%0.1%0.2 $0.26 12/15/202366,800 shares $16,472.88 +14.8%0.2%0.6 $0.25 11/30/202358,200 shares $12,804.00 -62.3%0.2%0.5 $0.22 11/15/2023154,300 shares $37,032.00 +16.1%0.4%1.2 $0.24 10/31/2023132,900 shares $33,278.16 -16.8%0.4%0.9 $0.25 10/15/2023159,800 shares $40,749.00 +56.4%0.4%1 $0.26 9/30/2023102,200 shares $24,640.42 +122.2%0.3%0.4 $0.24 9/15/202346,000 shares $12,880.00 -12.9%0.1%0.1 $0.28 8/31/202352,800 shares $13,780.80 -76.7%0.1%0.1 $0.26 8/15/2023227,000 shares $59,996.10 +22.3%0.6%0.4 $0.26 7/31/2023185,600 shares $51,040.00 -15.6%0.5%0.3 $0.28 7/15/2023219,900 shares $73,402.62 -1.7%0.6%0.4 $0.33 6/30/2023223,600 shares $69,763.20 +9.3%0.6%0.4 $0.31 6/15/2023204,600 shares $71,589.54 +53.5%0.6%0.5 $0.35 5/31/2023133,300 shares $30,019.16 -5.7%0.4%0.5 $0.23 5/15/2023141,400 shares $42,391.72 -12.8%0.4%0.9 $0.30 1/29/2021102,800 shares $47,550.14 +411.4%N/A0.1 $0.46 1/15/202127,100 shares $13,818.29 +118.6%N/A0 $0.51 12/31/202010,200 shares $4,386.00 -62.4%N/A0 $0.43 12/15/202027,100 shares $7,859.00 +118.6%N/A0 $0.29 11/30/202012,400 shares $2,168.76 -34.7%N/A0 $0.17 11/15/202019,000 shares $3,467.50 -54.2%N/A0 $0.18 10/30/202041,500 shares $8,590.50 +24.3%N/A0.1 $0.21 10/15/202033,400 shares $6,680.00 +59.8%N/A0 $0.20 9/30/202020,900 shares $3,657.50 +770.8%N/A0.1 $0.18 9/15/20202,400 shares $408.00 -81.5%N/A0 $0.17 8/31/202013,000 shares $2,382.90 +20.4%N/A0.1 $0.18 8/14/202010,800 shares $1,922.40 -26.5%N/A0 $0.18 7/31/202014,700 shares $2,940.00 -30.7%N/A0 $0.20 7/15/202021,200 shares $4,452.00 -0.5%N/A0.1 $0.21 6/30/202021,300 shares $2,982.00 -47.4%N/A0.1 $0.14 6/15/202040,500 shares $8,505.00 +130.1%N/A0.3 $0.21Dems have chosen Biden replacement? (Ad)On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.See who it is HERE. GTBP Short Interest - Frequently Asked Questions What is GT Biopharma's current short interest? Short interest is the volume of GT Biopharma shares that have been sold short but have not yet been covered or closed out. As of April 30th, investors have sold 6,000 shares of GTBP short. 0.48% of GT Biopharma's shares are currently sold short. Learn More on GT Biopharma's current short interest. What is a good short interest percentage for GT Biopharma? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.48% of GT Biopharma's floating shares are currently sold short. Is GT Biopharma's short interest increasing or decreasing? GT Biopharma saw a increase in short interest in April. As of April 30th, there was short interest totaling 6,000 shares, an increase of 81.8% from the previous total of 3,300 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is GT Biopharma's float size? GT Biopharma currently has issued a total of 1,380,000 shares. Some of GT Biopharma's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. GT Biopharma currently has a public float of 1,240,000 shares. How does GT Biopharma's short interest compare to its competitors? 0.48% of GT Biopharma's shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to GT Biopharma: Artelo Biosciences, Inc. (0.15%), Tharimmune, Inc. (1.03%), Alzamend Neuro, Inc. (0.47%), Kazia Therapeutics Limited (0.53%), Exicure, Inc. (1.75%), Evoke Pharma, Inc. (0.56%), GeoVax Labs, Inc. (0.32%), Ensysce Biosciences, Inc. (0.14%), Soligenix, Inc. (6.22%), ZyVersa Therapeutics, Inc. (2.08%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short GT Biopharma stock? Short selling GTBP is an investing strategy that aims to generate trading profit from GT Biopharma as its price is falling. GTBP shares are trading up $0.21 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against GT Biopharma? A short squeeze for GT Biopharma occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of GTBP, which in turn drives the price of the stock up even further. How often is GT Biopharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including GTBP, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: ARTL Short Interest Data THAR Short Interest Data ALZN Short Interest Data KZIA Short Interest Data XCUR Short Interest Data EVOK Short Interest Data GOVX Short Interest Data ENSC Short Interest Data SNGX Short Interest Data ZVSA Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:GTBP) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceInvest in the "Trojan Horse" of Alzheimer's TreatmentBehind the Markets348 million Americans lives to END as we know it?The Oxford ClubGold Set to EXPLODE!Gold Safe Exchange[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsHow Biden has already won 2024Porter & CompanyA once-in-a-century investment opportunityStansberry ResearchCharles Payne Demystifies OptionsUnstoppable Prosperity